Prostate cancer remains a significant global health concern, predominantly affecting men. In recent groundbreaking research led by Dr. Henrik Grönberg, a novel approach known as outcome adaptive design was implemented to revolutionize the assessment of different drugs simultaneously. This innovative study design incorporated the dynamic adjustment of randomization probabilities based on individual patient outcomes, enabling the selection of the most suitable treatment for each person. Furthermore, the study harnessed the power of biomarkers, particularly circulating tumor DNA, to guide treatment selection, ultimately aiming to enhance patient outcomes and overall quality of life.
Q: Can you elaborate for us more abuout your study design of your recent research?
A: In which you can compare many different drugs at the same time. But using what we call an outcome adaptive design Is that you change the randomization probabilities over the study design. Based on the results from each patient. So that means that the study becomes clever and clever to select the right treatment to the right patient. But we also use biomarkers. And biomarkers that we use are circulating tumor DNA. That’s a simple blood test that we measure about 75 genes that are important for prostate cancer. And what we do is then use these circulating tumor DNA biomarkers to randomize patients to different treatments based on these biomarkers. The main results today that I show you is that we compare standard of care which is physician’s choice to androidine receptor inhibitors that’s aberratharone and ancillotamide to taxanes.
And we showed that androidine receptor inhibitors were superior to both taxanes and physicians choice. If you look at progression -free survival which is the time to you have progression of your disease, it increased between five and six months.
But we also looked at the secondary endpoint at overall survival which means that these patients treated with androidine receptor inhibitors lived about 15 months longer than those put on taxanes or physicians choice.
And what kind of implications will this have in the future? I would say that if a man is treated with an ancillotamide receptor With metastatic prostate cancer hasn’t received an endorrhoea receptor inhibitor before, he should receive that before he receives taxanes.
The other thing that this study shows is that you can actually have a novel study design like ProBio using prospective biomarkers, adaptive randomization, in comparing many different treatments at the same time.
For example, Litytium can work for a subset of men with metastatic prostate cancer. I think one of the key things today in the session I did in my presentation is that bone health agents, that means that you should support bone health so you don’t get fractures during treatment with hormones in men with metastatic prostate cancer.
I think that’s one of the key take -home messages from this congress.
